Kwon K A, Diestelhorst M, Süverkrüp R
Pharmazeutisches Institut, Universität Bonn, Pharmazeutische Technologie.
Klin Monbl Augenheilkd. 1996 Aug-Sep;209(2-3):144-9. doi: 10.1055/s-2008-1035294.
In opthalmic suspensions, the mean dose and the uniformity of amounts administered in single drops depend upon the redispersibility of drug particles by shaking. The present article is a contribution to the development of the experimental and theoretical basis for a reproducible test, by which the dose uniformity of suspension eyedrops can be assessed under therapeutically relevant conditions. The requirement that suspension eyedrops and similar dosage forms should be redispersable after sedimentation upon storage is stated in the monographs on eyedrops of the German Pharmacopoeia and can be found in similar contexts in other pharmacopoeias. Until now, however, no corresponding test method has been specified.
Shaking profiles were recorded in 31 subjects and 27 patients using an acceleration sensor. They were compared with the acceleration profile of a computer-controlled pneumatic shaker and sampler. Both frequency and intensity of the shaking action were quantified by Fourier analysis of the acceleration profiles. The drug content of single drops of Isopto-dex (0.1% dexamethasone), Chibro-Amuno 3 (1% indomethacin), and Inflanefran-forte (1% prednisolone acetate) was assessed exhaustively in four 5-ml specimens of each ophthalmic suspension using the apparatus. The dose uniformity of single drops of suspension eyedrops was measured by UV-spectrophotometry for the entire contents of bottles. Four samples per day were drawn after six shaking cycles for approximately 4 weeks with three intervals of 4 h during daytime and 1 interval of 12 h during the night.
The shaking intensity of patients was lower than that of healthy subjects, while the frequency was similar for both groups. The intensity of the apparatus corresponds to the 67th percentile of the patients and to the 18th percentile of the healthy subjects. It was sufficiently close to the central values of both distributions to allow comparisons. for Isopto-dex, the mean drug content of 9.5 microns per drop amounted to only 25% of the value expected after complete redispersion, with a coefficient of variation (CV) of 23%. The mean value for Chibro-Amuno 3 was 93% of the expected quantity of indomethacin with a CV of 34%, while the mean content of Inflanefran-forte drops was 95% of the labelled dose with a CV as low as 9%.
The drug content of single drops of ophthalmic suspensions can be studied under well-defined and reproducible conditions by means of a computer-controlled pneumatic shaking and sampling apparatus. Under the conditions prevailing in this study, the solidified sediment of Isopto-dex was incompletely redispersed, so that doses were significantly too low. A variable dosing pattern with acceptable mean was observed for Chibro-Amuno 3, while the results for Inflanefran-forte were fully satisfactory.
在眼科混悬剂中,单滴给药的平均剂量和剂量均匀性取决于振摇后药物颗粒的再分散性。本文为建立一种可重复测试的实验和理论基础做出了贡献,通过该测试可在治疗相关条件下评估混悬型滴眼液的剂量均匀性。德国药典滴眼液专论中规定了混悬型滴眼液及类似剂型在储存后沉淀应可再分散的要求,其他药典也有类似规定。然而,到目前为止,尚未指定相应的测试方法。
使用加速度传感器记录了31名受试者和27名患者的振摇曲线。将其与计算机控制的气动振摇器和采样器的加速度曲线进行比较。通过对加速度曲线进行傅里叶分析来量化振摇动作的频率和强度。使用该装置对每种眼科混悬剂的四个5毫升样本中的异氟米松(0.1%地塞米松)、奇布罗 - 阿穆诺3(1%吲哚美辛)和强氟炎(1%醋酸泼尼松龙)单滴药物含量进行了详尽评估。通过紫外分光光度法测量混悬型滴眼液单滴的剂量均匀性,针对整瓶内容物进行测定。在大约4周的时间里,每天在六个振摇周期后抽取四个样本白天每隔4小时抽取一次,夜间抽取一次,间隔12小时。
患者的振摇强度低于健康受试者,而两组的频率相似。该装置的强度对应于患者的第67百分位数和健康受试者的第18百分位数。它与两个分布的中心值足够接近,便于进行比较。对于异氟米松,每滴平均药物含量为9.5微克,仅为完全再分散后预期值的25%,变异系数(CV)为23%。奇布罗 - 阿穆诺3的平均值为吲哚美辛预期量的93%,CV为34%,而强氟炎滴眼液的平均含量为标示剂量的95%,CV低至9%。
借助计算机控制的气动振摇和采样装置,可以在明确且可重复的条件下研究眼科混悬剂单滴的药物含量。在本研究的条件下,异氟米松的固化沉淀物未完全再分散,导致剂量明显过低。奇布罗 - 阿穆诺3观察到可变的给药模式,平均剂量可接受,而强氟炎的结果完全令人满意。